Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Short term Debt (2019)

Avidity Biosciences (RNA) has disclosed Short term Debt for 1 consecutive years, with $2.8 million as the latest value for Q4 2019.

  • For the quarter ending Q4 2019, Short term Debt changed N/A year-over-year to $2.8 million, compared with a TTM value of $2.8 million through Dec 2019, changed N/A, and an annual FY2019 reading of $2.8 million, changed N/A over the prior year.
  • Short term Debt was $2.8 million for Q4 2019 at Avidity Biosciences.
  • Across five years, Short term Debt topped out at $2.8 million in Q4 2019 and bottomed at $2.8 million in Q4 2019.